



FIGURE 1




Treatment	% Inhibition (Day 16)	p-value
Compound 1 vs. Compound 1 + Docetaxel	75	0.01
Docetaxel vs. Compound 1 + Docetaxel	82	< 0.0001

FIGURE 2



Treatment	% Inhibition (Day 20)	p-value
Cmpd 1 vs. Cmpd 1 + Docetaxel	78	0.01
Docetaxel vs. Cmpd 1 + Docetaxel	62	0.04

FIGURE 3



Treatment	% Inhibition (Day 57)	p-value
Docetaxel vs. Compound 1 + Docetaxel	82	0.008





FIGURE 5



Treatment	% Inhibition	p-value
Cmpd 1 vs. Cmpd 1 + 5 -FU	78%	0.006
5-FU vs. Cmpd 1 + 5 -FU	76%	0.01

FIGURE 6





FIGURE 7



Tumor Growth Delay of Combination vs:	Days Delay	p-value
Compound 1	30	0.0005
Cisplatin	23	0.0009

NCI-H526 cells inoculated sc into athymic mice (n=10/group). When tumors were ~ 250mm<sup>3</sup>, oral dosing of Compound 1 at 40 mg/kg/day, STI-571 at 160 mg/kg/BID or vehicle control was initiated.

